BCX4430 Protects Macaques From Filovirus Infection.pdf

Okay, I need to create a concise summary of this Nature article about BCX4430 as a broad-spectrum antiviral against filoviruses. Let me start by reading through the provided text carefully.

The main points are: Filoviruses cause severe hemorrhagic fevers with high fatality rates. Current treatments are limited, so there's a need for broad-spectrum antivirals. BCX4430 is a new synthetic adenosine analogue that inhibits filovirus RNA polymerase by terminating RNA chains. It was tested in rodent models and protected monkeys even 48 hours post-infection. Also, it works against other viruses like bunyaviruses, arenaviruses, etc. This is the first report of such a drug in non-human primates.

I should make sure to mention the key findings: effectiveness against EBOV and MARV, the mechanism of action (non-obligate RNA chain termination), the broad-spectrum activity, and the significance of it being the first synthetic drug to show protection in non-human primates. Also, note the assays used (biochemical, reporter-based, primer-extension) and the results in different models.

Need to check if there's any specific data, like the IC90 value for HeLa cells. The article mentions that 25 mM BCX4430 gives 90% inhibition (IC90 ~5.4 mM). Also, the part about no toxicity in human cells when concentrations are above MARV IC50 by tenfold is important for safety.

Avoid adding any extra information not in the text. Keep it detailed but concise, in English, without titles or markers. Start directly with the content. Make sure to highlight the novelty and the potential for public health applications. Mention the families of viruses it targets beyond Filoviridae. Also, note that ribavirin isn't effective against filoviruses, so BCX4430 is a new option.

Check for any other key points: the study's context of previous attempts with virus-specific drugs, the importance of a single agent for multiple filoviruses, and the support from various assays. Also, the part about the mechanism requiring the parent compound to be converted to triphosphate, then monophosphate, leading to termination.

Structure the summary to first state the problem (filovirus threat), then introduce BCX4430 as the solution, explain its mechanism, mention the tests done (rodents, monkeys), the broad-spectrum activity, and the conclusion about its potential as a countermeasure. Keep it under the required length, so maybe 200-250 words. Ensure all critical data points are included without fluff.

BCX4430, a novel synthetic adenosine analogue, demonstrates broad-spectrum antiviral activity against filoviruses and multiple other RNA viruses. It inhibits viral RNA polymerase function by non-obligate RNA chain termination, requiring conversion of the parent compound to BCX4430-triphosphate (BCX4430-TP) for activity. In rodent models, post-exposure intramuscular administration of BCX4430 protected against Ebola and Marburg virus disease, with complete protection of cynomolgus macaques even 48 hours after infection. The drug also exhibits efficacy against bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses, and flaviviruses, as shown in high-content imaging and neutral-reduptake assays. Unlike ribavirin, which is ineffective against filoviruses, BCX4430’s mechanism involves phosphorylation to BCX4430-TP, which disrupts viral RNA synthesis by terminating nascent chains during transcription and replication. In virus-infected cells, BCX4430 reduced surface glycoprotein expression and intracellular/extracellular RNA production for Marburg and Ebola viruses. At 25 mM, it achieved 90% inhibition of MARV in HeLa cells (IC90 ~5.4 mM), with no detectable incorporation into human RNA or DNA at concentrations exceeding MARV IC50 by tenfold. These findings support BCX4430’s potential as a broad-spectrum antiviral for filovirus and other viral diseases. This is the first report of a synthetic drug-like small molecule protecting non-human primates from filovirus disease, offering a cost-effective, multi-virus therapeutic option critical for public health preparedness.